Epidermal growth factor receptor family (EGFR, ErbB2–4) in gliomas and meningiomas
- 435 Downloads
Overexpression of epidermal growth factor receptor (EGFR, ErbB1) correlates with enhanced malignant potential of many human tumor types including glioblastoma multiforme. The significance of EGFR expression in meningiomas is, however, unclear. Reports regarding the other EGFR family members, ErbB2–4, in brain tumors are sparse. In this study, the expression of the EGFR family members was analyzed in relation to various parameters for the clinical importance of these receptors in 44 gliomas and 26 meningiomas. In gliomas, quantitative real-time reverse transcription (RT)-PCR revealed the highest EGFR mRNA expression in high-grade gliomas, while ErbB2 and ErbB3 mRNA were detected only in a few high-grade gliomas. In contrast, ErbB4 expression was most pronounced in low-grade gliomas. Immunohistochemistry showed significantly higher EGFR protein expression in high-grade gliomas compared to low-grade gliomas (P=0.004). ErbB2 protein expression was mainly seen in high-grade gliomas. ErbB3 protein expression was low in all gliomas analyzed. ErbB4 protein expression was significantly higher in low-grade gliomas than in high-grade gliomas (P=0.007). In meningiomas, quantitative real-time RT-PCR revealed expression of EGFR, ErbB2, and ErbB4 mRNA in the majority of the tumors. ErbB3 was detected in only one of the meningiomas analyzed. Immunohistochemistry demonstrated high ErbB2 protein expression in meningiomas. An intriguing observation in astrocytomas and oligodendrogliomas grade II, was a significantly decreased overall survival for patients with high EGFR protein expression (P=0.04). The high ErbB4 expression in low-grade compared to high-grade gliomas might suggest that ErbB4 acts as a suppressor of malignant transformation in brain tumors, which is in line with previous studies in other tumor types.
KeywordsEpidermal growth factor receptor ErbB2 ErbB3 ErbB4 Gliomas Meningiomas
This study was supported by grants from the Swedish Cancer Society and the Lion’s Cancer Research Foundation, Umeå University, Sweden. Kerstin Bergh is acknowledged for her excellent assistance with the immunohistochemical staining. We also thank Karin Andersson for secretarial assistance and Björn Tavelin for statistical help and advice.
- 3.Etienne MC, Formento JL, Lebrun-Frenay C, Gioanni J, Chatel M, Paquis P, Bernard C, Courdi A, Bensadoun RJ, Pignol JP, Francoual M, Grellier P, Frenay M, Milano G (1998) Epidermal growth factor receptor and labelling index are independent prognostic factors in glial tumor outcome. Clin Cancer Res 4:2383–2390PubMedGoogle Scholar
- 9.Haugen DR, Akslen LA, Varhaug JE, Lillehaug JR (1996) Expression of c-erbB3 and c-erbB4 in papillary thyroid carcinomas. Cancer Res 57:1184–1188Google Scholar
- 12.Hoang-Xuan K, He J, Huguet S, Mokhtari K, Marie Y, Kujas M, Leuraud P, Capelle L, Delattre JY, Poirier J, Broet P, Sanson M (2001) Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Neurology 9:1278–1281Google Scholar
- 15.Junttila TT, Sundvall M, Maatta JA, Elenius K (2000) Erbb4 and its isoforms: selective regulation of growth factor responses by naturally occurring receptor variants. Trends Cardiovasc Med 10:304–310Google Scholar
- 18.Kleihues P, Cavenee WK (eds) (2000) WHO Health Organization classification of tumours: tumours of the nervous system. IARC Press, LyonGoogle Scholar
- 19.Lee JC, Wang ST, Chow NH, Yang HB (2002) Investigation of the prognostic value of co-expressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer 38:1065–1071Google Scholar
- 26.Simmons ML, Lamborn KR, Takahashi M, Chen P, Israel MA, Berger MS, Godfrey T, Nigro J, Prados M, Chang S, Barker FG, Aldape K (2001) Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 61:1122–1128PubMedGoogle Scholar
- 27.Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O’Fallon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC, Jenkins RB (2001) PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93:1246–1256CrossRefPubMedGoogle Scholar
- 28.Thomasson M, Hedman H, Junttila TT, Elenius K, Ljungberg B, Henriksson R (2004) ErbB4 is down-regulated in renal cell carcinoma: a quantitative RT-PCR and immunohistochemical analysis of the epidermal growth factor receptor family. Acta Oncol (in press)Google Scholar